Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Marker Therapeutics (MRKR) EBITDA Margin (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed EBITDA Margin for 6 consecutive years, with 173.3% as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA Margin fell 4870.0% to 173.3% in Q3 2025 year-over-year; TTM through Sep 2025 was 876.59%, a 84738.0% increase, with the full-year FY2024 number at 5559.19%, down 547015.0% from a year prior.
  • EBITDA Margin was 173.3% for Q3 2025 at Marker Therapeutics, up from 494.79% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 93.29% in Q4 2024 to a low of 3528.01% in Q4 2023.
  • A 4-year average of 670.7% and a median of 400.28% in 2022 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: tumbled -312773bps in 2023, then soared 362129bps in 2024.
  • Marker Therapeutics' EBITDA Margin stood at 400.28% in 2022, then crashed by -781bps to 3528.01% in 2023, then surged by 103bps to 93.29% in 2024, then tumbled by -286bps to 173.3% in 2025.
  • Per Business Quant, the three most recent readings for MRKR's EBITDA Margin are 173.3% (Q3 2025), 494.79% (Q2 2025), and 1320.14% (Q1 2025).